| |
|
|
| |
Drug Reconstitution at the Point-of-Care
Therapeutic Markets, Technologies, Strategies and
Prospects
|
Publication: January 2012
Product Code: DRP222F
|
The inherent instability of biological drugs is a limitation
that has a direct impact on the drug delivery sector.
Therapeutic proteins must either be stored under special
conditions or formulated to retain their efficacy from the
time of manufacture until they are dispensed. Liquid protein
drugs require refrigeration until dispensed – a distribution
strategy referred to as the ‘Cold Chain’. Alternatively,
proteins can be formulated as powders (lyophilization).
Lyophilized proteins must be reconstituted prior to
injection. Lyophilized drugs are sold with reconstitution
vial systems, or packaged in special injection devices
(e.g., pens, needle-free injectors, two-part syringes) that
allow reconstitution to take place in the device prior to
injection. As biological drugs continue to grow in terms of
therapeutics and total prescriptions, the impact of
specialty devices will increase. |
|
Highlights |
· Analyzes therapeutic
demand drivers and evaluates the market impact and
potential of commercial drug reconstitution systems
· Provides analysis of
injectable lyophilized drugs and assess key market
segments, market dynamics and market demographics
· Forecasts Injectable
drug product demand by indication and therapy to 2016
· Profiles reconstitution
system suppliers, their product activities,
business strategies, and corporate alliances and
affiliations
|
|
Summary of Contents |
Executive Summary
Market Dynamics
Prolonging the Shelf Life of Biological Drugs
Distribution Strategies
Formulation Strategies
Lyophilization and Reconstitution at the Point of
Use
Healthcare Economics and Reconstitution
Systems
What’s Driving the Growth in Engineered
Reconstitution Systems?
Biological Drugs
Proliferating
The Trend toward
Self-Administration
Shifting Demographics
Innovation in Disposable Device Designs
Therapeutic Demand Drivers
Competitive Landscape
Risk Factors
Drug Reconstitution Systems –
Commercial Devices
Vial Adapters
Vial-to-Vial
Systems
Needle-less Transfer Devices
Direct
Connect to Vial
Direct Connect to Cartridge
Dual Chamber Syringes
Dual Chamber Cartridges
Closed Drug Transfer
Reconstitution System
Design Factors
Stability and Material Selection
Issues
Disposable Drug Cartridges
Single vs
Multi-Dose Devices
Human Engineering/Ergonomics
Drug Reconstitution - Therapeutic Sector Analysis
Antibiotics/Antivirals
Antibodies
Autoimmune
Diseases
Arthritis
Crohn’s Disease
Lupus
Multiple Sclerosis
Psoriasis
Blood
Proteins
Hepatitis
Hemostats
Hormone
Replacement
Human Growth Hormone
Oncology
Osteoporosis
Reproductive Medicine
Vaccines
Market Sector Drivers
Competitive Climate
Osteoporosis Therapies Supplied as Lyophilized Drugs
Reproductive Health
Reproductive Therapies
Supplied as Lyophilized Drugs
Market Factors
Syringe Disposal
Regulatory Issues
Patient
Compliance
Healthcare Economics
Drug
Reconstitution Systems - Company Profiles
|
|
|
|
|
